1/27
Vocabulary flashcards covering key concepts, neuroimaging techniques, neurotransmitters, and psychotropic drug classes from Chapter 4.
Positron-Emission Tomography (PET) and SPECT
Neuroimaging techniques that localize brain regions associated with perceptual, cognitive, emotional, and behavioral functions, providing evidence of metabolic changes in unmedicated individuals with depression, schizophrenia, or OCD.
Functional Magnetic Resonance Imaging (fMRI)
A neuroimaging technique that measures how well two regions of the brain communicate with each other, demonstrates cognitive function, and may eventually predict treatment response to medications.
Reuptake
The process by which a neurotransmitter, after interacting with the postsynaptic receptor, is released from the receptor and taken back into the presynaptic cell.
Receptor Agonist
An extrinsic drug that binds to and controls a cell receptor, producing the same biological effect as intrinsic substances.
Receptor Antagonist
An extrinsic drug that binds to a receptor site and blocks it, preventing intrinsic substances from binding.
Pharmacokinetic Drug Interactions
Interactions that occur when one drug alters the absorption, distribution, metabolism, or elimination of another drug, thereby affecting its plasma concentrations.
Pharmacodynamic Drug Interactions
Interactions that occur when drugs act at the same or interrelated receptor sites, resulting in synergistic or antagonistic effects.
Polypharmacy
The concurrent use of multiple medications by a patient, which complicates the management of drug interactions, especially in older adults.
Monoamine Oxidase (MAO)
An enzyme that destroys monoamine neurotransmitters, including catecholamines and indolamines.
Monoamine Oxidase Inhibitors (MAOIs)
Antidepressant drugs such as phenelzine, tranylcypromine, and transdermal selegiline that increase concentrations of monoamines by inhibiting the MAO enzyme.
Hypertensive Crisis
A severe adverse reaction occurring when a patient taking MAOIs ingests tyramine-containing foods (such as aged cheese, beer, wine, organ meats, and avocados) or certain OTC medications.
Antidepressant Discontinuation Syndrome
A withdrawal syndrome caused by abruptly stopping SSRIs, characterized by the FINISH mnemonic: Flu-like symptoms, Insomnia (with vivid dreams), Nausea, Imbalance (dizziness/vertigo), Sensory disturbances, and Headaches.
Serotonin Syndrome
A potentially life-threatening condition caused by excessive serotonin activity (mnemonic SHIVERS: Shivering, Hyperreflexia, Increased temperature, Vital sign instability, Encephalopathy, Restlessness, Sweating), treated with cyproreptadine.
Anticholinergic Toxidrome
A collection of side effects resulting from muscarinic cholinergic receptor blockade, summarized as 'Blind as a bat' (mydriasis), 'Mad as a hatter' (confusion), 'Red as a beet' (flushed skin), 'Hot as a desert' (hyperthermia), and 'Dry as a bone' (dry mouth, urinary retention).
Buspirone (Buspar)
An anxiolytic drug that reduces anxiety without producing the sedative and euphoric effects associated with benzodiazepines.
Z-hypnotics
Short-acting nonbenzodiazepine sedative-hypnotic sleep agents (zolpidem, zaleplon, eszopiclone) that provide sedative effects without the antianxiety, anticonvulsant, or muscle relaxant effects of benzodiazepines.
Ramelteon (Rozerem)
A melatonin-receptor agonist hypnotic drug thought to regulate circadian rhythms.
Lithium Blood Level Thresholds
Blood concentration parameters for lithium therapy: acute therapeutic level of 1 to 1.5 mEq/L, maintenance level of 0.6 to 1.2 mEq/L, and toxic level above 2.0 mEq/L.
Lamotrigine (Lamictal)
An anticonvulsant mood stabilizer effective in bipolar depression that carries a risk of triggering Stevens-Johnson syndrome (SJS), a severe skin reaction.
Carbamazepine (Tegretol)
An anticonvulsant mood stabilizer effective for rapid cycling bipolar disorder that may cause rare but serious blood dyscrasias.
Positive Symptoms of Schizophrenia
Psychotic symptoms that are present and should not be there, including visual and auditory hallucinations, delusional thinking, disorganized behavior and speech, and agitated or repetitive movements.
Negative Symptoms of Schizophrenia
The absence of normal behavioral functions that should be present, including flat or blunted affect, isolation, apathy, anergia, anhedonia, and reduced speech.
First-Generation Antipsychotics (FGAs)
Conventional antipsychotics (e.g., haloperidol, fluphenazine, chlorpromazine) that act as D2 dopamine receptor antagonists to reduce positive symptoms, but carry a significant risk of extrapyramidal side effects.
Extrapyramidal Side Effects (EPS)
Drug-induced movement disorders resulting from dopamine blockade, including pseudoparkinsonism, acute dystonia, akathisia, and tardive dyskinesia.
Akathisia
An extrapyramidal side effect characterized by motor restlessness, trouble standing still, pacing, and constant movement of the feet or rocking back and forth.
Tardive Dyskinesia
A late-onset extrapyramidal side effect characterized by involuntary movements such as tongue protrusion and rolling, lip sucking and smacking, chewing motions, and facial or extremity dyskinesia.
Neuroleptic Malignant Syndrome (NMS)
A rare, life-threatening adverse reaction to antipsychotics defined by the NMS Tetrad: altered mental status (AMS), hyperthermia (temp), autonomic instability, and muscular rigidity.
Second-Generation Antipsychotics (SGAs)
Atypical antipsychotics (e.g., clozapine, olanzapine, risperidone, quetiapine) that target both positive and negative schizophrenia symptoms with lower EPS risk, but carry a risk of metabolic syndrome.